Zomig 5 mg Tablets

Zomig 5 mg tablets for acute migraine treatment

Zomig 5 mg tablets contain zolmitriptan, a triptan used to treat a migraine attack after it has started. This product is an oral tablet for acute treatment, not a daily preventive medicine or a general-purpose painkiller. That distinction should guide the purchase decision: Zomig may be relevant when a triptan has been recommended for an established migraine pattern, whereas a preventive treatment is intended to reduce how often attacks occur.

The exact product in our catalogue has one strength, 5 mg, so there is no choice between strengths on this listing. Instead, the practical questions are whether an oral triptan is appropriate for you, whether the 5 mg strength matches your instructions, and how many bottles you want to order. A prescriber or pharmacist should help with the clinical decision if you have not used zolmitriptan before or if your health or other medicines have changed.

Product identity and place in treatment

Zomig is the brand name and zolmitriptan is its active ingredient. It belongs to the triptan group of medicines, formally described as selective serotonin 5-HT1B/1D receptor agonists. The product covered here is specifically a conventional 5 mg tablet taken by mouth. It is not a nasal spray, an orally dispersible tablet, an injection, or a modified-release preparation.

Triptans are used for the headache phase of migraine with or without aura. They do not prevent future attacks and are not intended for routine daily use. NICE guidance includes triptans among the options for acute migraine treatment, sometimes alone and sometimes as part of a treatment plan involving another suitable medicine. The right approach depends on previous response, tolerability, other health conditions, and the pattern of the attacks.

Who might consider Zomig 5 mg tablets?

Zomig may be considered by an adult with a recognised migraine pattern who has been advised that a triptan is suitable. It should not be used to diagnose an unfamiliar headache or to assume that a new set of symptoms is migraine. Seek medical advice for a first severe headache, a major change in the usual pattern, or symptoms that could suggest another cause.

Factors that deserve particular attention before using or ordering this strength include:

• Previous response: someone who has already responded well to zolmitriptan may reasonably wish to continue the same medicine, while a poor response may justify discussing timing, diagnosis, dose, or another treatment.
• Heart and circulation history: zolmitriptan may not be suitable for people with coronary heart disease, coronary artery spasm, peripheral vascular disease, previous stroke or transient ischaemic attack, or uncontrolled high blood pressure.
• Cardiovascular risk: risk factors such as diabetes, smoking, high cholesterol, high blood pressure, or a strong family history may make an assessment appropriate before treatment begins.
• Pregnancy: zolmitriptan is not usually recommended during pregnancy because information about its use in humans is limited. A clinician can discuss alternatives and the balance of possible benefit and risk.
• Breastfeeding: caution is advised because human exposure information is limited. Supplied guidance recommends avoiding breastfeeding for 24 hours after treatment to minimise infant exposure.
• Age: these tablets are intended for adults and are not recommended for children or adolescents under 18 because safety and effectiveness have not been established for this age group.

An allergy to zolmitriptan or any ingredient in the tablet rules out its use. Check the patient information leaflet for the complete ingredient list rather than relying on a general history of allergies.

How does zolmitriptan work?

Zolmitriptan activates 5-HT1B and 5-HT1D serotonin receptors involved in migraine. Its effects include reducing signalling through the trigeminal pain pathway, limiting the release of certain neuropeptides, and constricting selected cranial blood vessels. Migraine biology is more complex than blood-vessel widening alone, so the medicine should not be understood simply as a treatment that reverses one vascular change.

For the person taking it, the important point is that zolmitriptan acts during an attack. It may reduce headache pain and associated symptoms such as nausea and sensitivity to light or sound, but individual response varies. It does not remove the underlying tendency to have migraine, and a successful dose does not guarantee that symptoms will never return later in the same attack.

Using the oral tablet correctly

Follow the directions on the dispensing label and in the patient information leaflet. Zolmitriptan is generally taken after the migraine headache has begun and is best taken promptly once that headache is recognised. It can still be effective when taken later during an attack. Do not take it during aura solely in an attempt to prevent the headache unless a clinician has specifically advised you to do so.

The tablet is taken by mouth with water and may be taken with or without food. The supplied adult guidance permits a single 5 mg dose when needed, but that does not mean this strength is suitable for every person. Do not take another dose merely because relief is not immediate. Whether a repeat dose is allowed, the interval before it, and the maximum daily amount must follow the instructions supplied for your medicine.

A brief migraine record can make later treatment reviews more useful. Consider recording:

• when the headache began and when the tablet was taken;
• the main symptoms and their severity;
• whether meaningful relief occurred and how long it lasted;
• whether symptoms returned; and
• any unwanted effects or medicines taken at the same time.

Frequent reliance on medicines for acute migraine can contribute to medication-overuse headache. If attacks are becoming more frequent or you regularly need acute treatment, discuss the pattern with a clinician rather than simply increasing the amount kept at home.

Our available order quantities

We list Zomig 5 mg tablets in order quantities of one, two, three, four, or five bottles. These figures refer to the number of bottles, not the number of tablets in each bottle. Because our current listing does not state a tablet count per bottle, we do not convert these options into tablet totals or describe them as different tablet pack sizes.

Choose an order quantity only after confirming that the medicine and 5 mg strength match your directions. Ordering more bottles does not change the dose or make a higher dose appropriate. If you need clarification about the quantity shown in our listing, our support team can assist by email or online chat.

Store the tablets at 20°C to 25°C in a tightly closed container, protected from light and moisture. Keep them out of the sight and reach of children, and do not use tablets after the stated expiry date.

How quickly can relief occur?

Response differs between people and between separate attacks in the same person. Some improvement may be noticed during the first hour, but oral triptan outcomes are commonly assessed over the following two hours. A slower response does not justify taking extra tablets sooner than the product instructions allow.

Useful outcomes include reduced headache intensity, improvement in nausea or sensitivity to light and sound, and the ability to resume normal activities. Complete relief is possible but not guaranteed. Symptoms can also return after an initial response. If this repeatedly happens, a prescriber may review the timing of treatment, the dose, or whether a triptan with a different duration of action would be more suitable.

Seek medical advice if zolmitriptan repeatedly has little effect. Do not assume that every severe or recurring headache should be treated with another dose, particularly if the symptoms differ from your established migraine pattern.

Important safety priorities

Zolmitriptan can affect blood vessels, so heart and circulation conditions are central to its safety assessment. It should not be used by people for whom a triptan is contraindicated, including those with certain forms of heart or vascular disease, a previous stroke or transient ischaemic attack, or uncontrolled high blood pressure. The complete restrictions in the patient information leaflet and dispensing directions take priority over this general guide.

Possible unwanted effects include dizziness, drowsiness, weakness, nausea, tingling, warmth, or sensations of pressure or tightness. Migraine itself can cause some of the same symptoms. Do not drive, cycle, or operate machinery if the attack or the medicine makes you drowsy, dizzy, weak, or unable to concentrate safely.

Chest, throat, neck, or jaw pressure can occur with triptans, but severe, persistent, or unfamiliar chest pain requires urgent medical assessment. Do not take another dose while possible heart-related symptoms are being assessed. Emergency help is also appropriate for signs of a serious allergic reaction, such as facial or throat swelling, difficulty breathing, or collapse.

Suspected adverse reactions can be reported through the MHRA Yellow Card Scheme. Reporting helps the UK regulator monitor medicine safety, but it does not replace seeking prompt care when symptoms are urgent.

Which interactions and precautions matter?

Give a prescriber or pharmacist a complete list of prescription medicines, non-prescription products, and supplements before using zolmitriptan. The most important combinations include medicines that also constrict blood vessels or alter serotonin activity.

• Other triptans: do not combine zolmitriptan with another 5-HT1 agonist. Product information generally requires at least 24 hours between them.
• Ergotamine and related medicines: these should not be taken at the same time as zolmitriptan. UK product information uses different intervals in each direction: zolmitriptan should be delayed for at least 24 hours after an ergot-containing medicine, while an ergot medicine should be delayed for at least six hours after zolmitriptan.
• Antidepressants: SSRIs and SNRIs can rarely contribute to serotonin syndrome when combined with a triptan. Agitation, confusion, sweating, fever, diarrhoea, tremor, muscle twitching, or poor coordination require prompt advice.
• MAO-A inhibitors: medicines such as moclobemide can increase exposure to zolmitriptan and require a specific dose assessment.
• Other interacting medicines: cimetidine and strong CYP1A2 inhibitors, including fluvoxamine and some quinolone antibiotics, may affect zolmitriptan levels and should be checked by a healthcare professional.

Do not use zolmitriptan within the restricted interval for another triptan or ergot medicine even if the first treatment did not work. Combining acute migraine medicines without checking their compatibility can increase risk without guaranteeing better relief.

Conditional comparison with other migraine treatments

Zolmitriptan is one of several triptans. Sumatriptan, rizatriptan, eletriptan, almotriptan, naratriptan, and frovatriptan act through related receptors, but they differ in onset, duration, available forms, interactions, and individual tolerability. A medicine that works well for one person may be ineffective or cause unwanted effects for another, so Zomig should not be presented as universally better.

Dihydroergotamine and ergotamine are older migraine medicines with different practical limitations and safety considerations. They are not interchangeable with zolmitriptan, and the timing restrictions between these medicines matter. None of the named alternatives is listed as a product sold in our current catalogue; they are included to support a conditional discussion with a prescriber.

For a broader view of the relevant product area, you can also visit our migraine treatments category. Category placement does not establish that every listed option is suitable for the same person or can be used together.

UK prescription context

Zolmitriptan 5 mg tablets are Prescription Only Medicines in the United Kingdom. That classification is determined by UK regulation and remains separate from the way an online ordering process begins. NICE recognises triptans such as zolmitriptan as options for treating acute migraine attacks, but guidance does not replace an individual assessment or a valid prescription where one is required for supply.

Our ordering policy does not require you to present an existing paper prescription before beginning an order. This does not alter Zomig's Prescription Only Medicine status or remove any authorisation that must be in place before the medicine can lawfully be supplied. If you are uncertain about what our process requires, ask our team before confirming the order rather than treating checkout access as evidence that the medicine is suitable for you.

How does ordering through us work?

Our catalogue offers Zomig 5 mg tablets in quantities of one to five bottles. Select the bottle quantity that matches what you intend to order, then review the product and GBP price information shown during our checkout. Do not choose a quantity by estimating an undocumented number of tablets per bottle.

1. Confirm that Zomig, zolmitriptan, the oral tablet form, and the 5 mg strength match the medicine you intend to order.
2. Select one, two, three, four, or five bottles from the options we offer.
3. Review the order details and any applicable requirements in our checkout before confirming.
4. Contact our support team if the medicine, quantity, order status, or delivery information is unclear.

Our support team is available 24/7 by email and online chat, and pharmacist support is available. We do not state a delivery estimate or make claims about local stock, customs, insurance, reimbursement, or guaranteed arrival because none of those details is supplied for this listing.

A focused decision summary

Zomig 5 mg tablets are a specific oral triptan option for treating an acute migraine attack after it begins. The medicine is not intended for daily prevention, and the listing does not offer a choice of strengths. Before ordering, confirm that zolmitriptan is appropriate for you, that 5 mg matches your directions, and that no cardiovascular condition, pregnancy consideration, allergy, or medicine interaction changes the decision.

Our available quantity choice is between one and five bottles, not between packs containing one and five tablets. If the tablet count per bottle is important to your decision, ask our team rather than inferring it from the order quantity. The most appropriate choice is the one that matches valid clinical directions, your established response to treatment, and the exact product details - not simply the largest quantity available.